Document is current
Any future updates will be listed below
-
Authors
Gioia, Ubaldo https://orcid.org/0000-0002-4993-5283
Tavella, Sara https://orcid.org/0000-0003-4627-1589
Martínez-Orellana, Pamela
Cicio, Giada
Colliva, Andrea
Ceccon, Marta
Cabrini, Matteo
Henriques, Ana C.
Fumagalli, Valeria https://orcid.org/0000-0003-2583-2498
Paldino, Alessia
Presot, Ettore https://orcid.org/0000-0002-8446-0105
Rajasekharan, Sreejith
Iacomino, Nicola
Pisati, Federica
Matti, Valentina
Sepe, Sara
Conte, Matilde I.
Barozzi, Sara
Lavagnino, Zeno https://orcid.org/0000-0002-7247-8084
Carletti, Tea https://orcid.org/0000-0003-2510-2399
Volpe, Maria Concetta
Cavalcante, Paola
Iannacone, Matteo https://orcid.org/0000-0002-9370-2671
Rampazzo, Chiara https://orcid.org/0000-0002-1092-2653
Bussani, Rossana
Tripodo, Claudio https://orcid.org/0000-0002-0821-6231
Zacchigna, Serena https://orcid.org/0000-0001-6705-3076
Marcello, Alessandro https://orcid.org/0000-0002-8903-8202
d’Adda di Fagagna, Fabrizio https://orcid.org/0000-0002-9603-5966
- License Information
-
More Information
Article History
Received: 17 December 2021
Accepted: 25 January 2023
First Online: 9 March 2023
Competing interests
: M.I. participates in advisory boards/consultancies for Gilead Sciences, Roche, Third Rock Ventures, Antios Therapeutics, Asher Bio, Amgen, Allovir. All the other authors declare no competing interests.
